For those brainstorming startup ideas some relatively recently funded companies include:
eGenesis - Dr. George Church's company that uses edited porcine stem lines for human xenotransplantation
Twist Bio - synthetic bio for applications ranging from novel materials to data storage
Denali - focus on age related neurodegenerative disorders such as Parkinson’s and Alzheimer’s
Benchling - molecular bio and gene editing design software
Synthego - free gene knockout kits
But of all the breakthroughs last year. The one that may be most impactful. Editing human genes in the embryo to remove hereditary disease.
Correction of a pathogenic gene mutation in human embryos
Tech investors are almost totally unequiped to do the necessary DD. They either therefore go for plays that are easy to understand, largely computational exercises or in the rare cases they do go for something higher risk, they back something crazy (e.g. Theranos) because they don’t do good DD.
Getting an “expert” to vet the play rarely works. Because tech VCs don’t know how to choose good experts.
So most of (all?) these plays will ultimately fail. It won’t matter much to seed round investors though, because they’ll take 10 years to fail and they will likely have at least partially exited by then...
My observation during this dot-com boom is that a lot of the people who did well last round are now part of the VC infrastructure, like our own Paul Graham. My impression is that this time around, money is a lot more competent because of this.
Because this made such a huge impact on my life, I kinda want to extend it: perhaps the first round of any new technology is going to be littered with bad ideas. Perhaps that is necessary. Then perhaps those with experience can look backwards and do better next time.
I personally still think we are headed towards a second dot-com bust, but I've been saying that so long that at this point, I'm just wrong. Unquestionably, the business and money people did their jobs much more skillfully this time around than they did in the '90s.
https://www.nature.com/articles/d41586-018-00335-8
Maybe the first startup YC should fund is one to mutate the enzyme to avoid immunoreactivity while preserving function...
There's a huge problem in non-transparent pricing for products. For those outside the industry it's like buying used cars, dealing with sales reps and everything is a quote. Researchers are at a huge informational disadvantage when it comes pricing.
Example, acetone which is a commonly used solvent:
https://i.imgur.com/QyJ1Tj5.png
https://i.imgur.com/mJyfFfX.png
$900 vs. $300
Another example, IPTG:
https://i.imgur.com/tvnVAqO.png
We commonly see 3-5x differences and up to 10x for the exact same item. This makes a huge difference when you're in the range of 500k to 1 mil from YC Bio.
Interestingly, servers seem to be only 1.5x, and if you buy your servers in parts, the variance is even smaller.
If using your tech skills to help battle disease in an ambitious way is interesting and you wanna learn about a new, quiet startup (top-tier funders, world-class bio folks already on board for you to partner with, rare advisors from tech/bio/pharma), ping me: kamens@gmail.com
We're hiring a couple more for our early team and specifically looking for data, infra, and ML engineers. No specific bio background required. Staying quiet for now, can share more when we talk.
Sometimes, we have some promising leads on disease that we can begin to chase down. Most of the time, however, we have no idea where to begin, and so a shotgun basic science approach may ultimately be more fruitful. Every subfield is different and difficult to master, which is why it is so important to engage with the people who actually do the work.
I know the tone of this sounds like I'm beating a dead horse. I'm sorry.
Great to see YC address the lab space issue and give a larger cash/equity cut for biotech focused companies.
I am wondering how early/late stage the desired biotech company should be. Right now, many biotech-y YC applications/interview participants seem to be rejected with the comment that they should come back later.
It's great to see some targeted support for bio, though! It seems like a harder market division to get into than a pure tech company.
https://doi.org/10.1006/jtbi.2001.2430
You will see that there is no good way to compress the tail end of mortality and consequences resulting from accumulated unrepaired damage. The only cost-effective path is to postpone it indefinitely through periodic repair of that damage.
Aging is damage, and mortality/disability rises with damage. Effective treatments for aging are forms of repair of damage, of which only senolytics presently exist in any form that is available. Once you accept this model, you can start to reason about the effects of various approaches, and everything makes a lot more sense.
It seems to me a great deal more people face a very different question, "how can I afford to live longer?"
please, please, please, please, please, please, please ensure that at YC the people with money do not try to interpret laboratory data and stay far away from making any kind of project-level decisions.
it's something they (VCs) love to do, in my experience. incorrectly. and it's a massive waste of scientists' time, to have to correct the moneymen's misunderstandings of rudimentary things. then it's a cringe session when you hear them trying to explain it to other moneymen. then it's a big tearjerker when the moneymen's childlike expectations aren't met, and the company suffers.
something about biotech VCs and business types makes them think that they understand their products and products-in-development even if they're unqualified. the reality is that the depths of their ignorance are very embarrassing.
but i digress. i hate to rain on the parade here, but my bet is that most of the early stage biopharmas at YC will fail due to one of two reasons:
1. nature isn't working in the way they need it to.
2. the people with money don't stay out of the way enough and make stupid decisions that they don't understand.
i've seen a few biotechs fail to reason 1-- always tragic, but nature always has another trick that mankind will figure out some other day.
i've also seen a few fail to reason 2. it's very predictable, and saddening every time. non-technical types in leadership positions need to stay far away from biotech, especially at an early stage... they ruin things by cutting funding at the wrong time; they ruin things by forcing idiotic focuses; and they ruin things by believing that manipulating nature is similar to making a faster horse.
i have plenty of ideas on how to make biotech startups work better when they receive funding, however. they are, shall we say, politically incorrect-- both to the society of the scientists as well as the society of the VCs. perhaps i will share them on some other evening.
In the embedded/IoT industry, the majority of medical device innovation is centered around home monitoring/care for older patients in nursing homes, or for preventative/medicine.
Can anyone with experience in the bio/chem/pharma startup world point to good resources where we can get up to date on the most exciting/promising new bio tech/startups of the past 20 years or so? Also related - has anything come out of Alphabet Calico [1]?
Short answer: there is a "perfect storm" of innovation right now in bio. Tech from the 2000s genomic bubble is entering the mature phase of the hype cycle and ushering in a new era of potential curative therapy (gene therapy, cell therapy, personalized medicine). Avexis, a company treating a devastating neurological disease affecting infants using gene therapy, is ky favorite example to this
There is also the more widely hyped tech, AI, wearables, synthetic bio, etc, with massive potential, but these techs haven't had much impact on patients yet
Post here: http://newbio.tech/blog.html
E.g. some resources in which people are less than complimentary:
http://www.sens.org/research/research-blog/question-month-16...
https://www.technologyreview.com/s/603087/googles-long-stran...
https://www.vox.com/science-and-health/2017/4/27/15409672/go...
There are plenty of others if you want to go look for them.
There was a startup trying to make autoluminescent plants with jellyfish genes before CRISPR even existed, just using ordinary plasmid creation and transfection techniques.[1] That particular effort failed commercially, but I believe they recently reincorporated as 'GLEAUX'.
Anyways, Biology is messy and difficult, but I really think that we are getting to a reasonably solid understanding of genetically engineering plants. And once someone turns that into a '1, 2, 3' process...well I don't think you need more than a 5-figure investment for equipment/space.
[1]: http://journals.plos.org/plosone/article?id=10.1371/journal....
The perspective one takes on the biological system in question is vastly different depending on where you are coming from. Biologist understands bigger picture ideas about the system and can narrow down potential solutions. Tech injects more rigor and organization into how data is collected and analyzed. The skills are very complementary.
I am optimistic because I am seeing more people coming up in the field who are trying to do both molecular biology and data science.
I'm a professor at WashU and am interested, but I live in St. Louis.
YC's "move to the bay area" requirement makes sense for software startups, but less so for bio (at least for most of the good ideas).
https://techcrunch.com/2017/12/14/gingko-bioworks-secures-27...
That said, they said they've learned some lessons and they are providing more capital, and I'm sure if any organization can fix the biopharma seed exosystem it's them
The most important thing for them will be to get the right group of mentors. If you go off on the wrong scientific direction at the start of the company, it's much harder to salvage things with a pivot, so you need good eyes on all details of your experiments before you deploy capital
Biology is a very different field; stuff that is wonderfully promising can get help up for years based on trivial mistakes or simple strategic errors. And on top of that, 95% of the stuff that sounds great won't amount to anything, and you can't tell until a few years have passed.
Our understanding of molecular biology isn't nearly as plug-and-play as many would like it to be.
What could be better than glowing monkey grass leading up to your house? But as always, devil is in the details.
That said, it's true that we do also need to address healthcare costs - that is a huge problem and we would love to fund companies working on it.
I wrote about the opportunity in bio earlier this week and run a program connecting top tier scientists with life sci VCs. If you are interested in bio and don't have a science background, this is the best time ever to get involved: http://newbio.tech/blog.html
It's still not perfect, though, so the things we're trying in this experiment, like providing lab space for companies, are the next step.
I also can see no means to turn it into a business model or income stream, nor even get anyone interested in benefiting from what I know for free. It isn't the magic bullet people are looking for. A spartan life, eating better and lots of walking is not an answer people want. It also isn't an answer that investors will fund.
Meanwhile, hey, lung transplants and $300k/year new drugs for CF are all the rage. That makes headlines and apparently makes money.
A business model for healthcare seems to produce Frankensteinian outcomes. Things that are actually health promoting, like having a full-time parent to care for the kids and primary breadwinner, eating right, exercise etc are boring and don't make VCs rich. They are actually quite challenging to promote at all.
I wish I saw it differently.
I'm not claiming to do better: my "give a motivational speech when I see you in clinic twice a year" approach certainly isn't worth shit.
But just because one approach is important does not mean others are snake oil. CF has a clear biological basis, and there are randomized, controlled trials proving that secretion management (e.g. DNase), glucose control, timely antibiotics and anti-inflammatory meds, and chest physiotherapy work. These trials also establish an average effect size (whereas your anecdote only tells me about you; I have also had patients who took similar measures but still died young). The average person with CF died at age 25 in 1986 -- today it's above 40.
The current mental model is that people with CF overproduce mucus and are drowning in their own mucus. I believe this to be incorrect. We underproduce mucus. Giving the body what it needs to produce enough mucus makes a big difference. Inadequate mucus production is one of the ways the body's immune system is compromised and fixing that is entirely about proper nutrition.
I am well aware of the increase in life expectancy thanks to better drugs. I also used to take about 8 or 9 maintenance drugs and they made life not worth living. I was in constant excruciating pain for 3.5 years. No amount of pain medication really stopped it and my sleep quality was atrocious. I got better in part because I wanted to hurt less and I did not care if that accidentally killed me.
I had a life before my diagnosis. After my diagnosis, all I had was drugs staving off death. I frankly can't comprehend why more people with CF don't commit suicide. It's a horrible way to live.
All the drugs have a six page handout listing side effects. They trade short term gains for long term costs, take credit for the benefits and blame your genes for long term negative impacts.
I am not against drugs. I was thrilled to get a diagnosis and be able to ask for Zithromax up front. But there are things very, very wrong with our current approach. If anyone but a doctor did such terrible things to someone, they would be charged with a crime.
I think I was unwelcome on CF lists in part because people who had literally tortured themselves or their child balked at hearing that maybe you don't have to be tortured. I think accepting the torture and making their peace with it was a necessary psychological survival mechanism and they probably could not even name their objection to what I was saying.
I don't hate physicians either. I'm having a terrible, terrible day and speaking to these issues on HN is basically evidence that I have finally snapped. I don't like hurting other people. But trying to not hurt other people is essentially killing me. These are things I cannot discuss anywhere. It isn't socially acceptable. And that is part of the problem. Other people not only can't speak of it, many seem incapable of even thinking about it. It isn't acceptable for someone with CF to want a life. Just not dying yet is supposed to be all we aspire to and that's it. And I am incapable of swallowing that.
Today we have more leisure time than ever before in human history (well ... maybe not the HN crowd) but we're spending that time in increasingly sedentary hobbies/interests.
As a physician, does the idea that manufacturing and robotics will completely eliminate our need to work scare you at all? If the trend continues, will we truly be the space-faring humans in Wall-E - tied to our mechanical chairs and handicapped by our girth while life-spans decrease due to obesity-related diseases?
Like you, I spend a lot of time figuring out how to live better. But also grateful for the medicine I got for illnesses when they do arise.
I use and apply free health advice. Then again, I also use gym and supplements, which may have made VCs rich. Likewise, in cures, I appreciate that they are available in the low probability I get seriously ill. I am sure many suffering from alzheimer, cancer or other age-related diseases, would want there to be cures.
In the goal increasing healthspan, can't one favour the all-of-the-above approach? Primarily rely on healthy living like you suggest, yet support people developing cures for diseases.
PS. Almost all cures come from the US, 57 % of them, and 13 % from Switzerland. While this health care system is dysfunctional in many ways, it also is the market new cures are being developed for. In Europe, where I am from, most drugs are purchased by a single large purchaser, which has negotiation power to buy a drug at close to marginal cost. This makes drugs cheaper, but also makes less people try to invent new cures. So, it's a bit of a trade-off between the present and the future.
I quit taking the flu vax years ago and have done better since. In the eyes of some people, this makes me a nutcase antivaxxer even though flu vaccines are not required.
When I was growing up, anyone getting vaccinated was a success. People who didn't weren't all that uncommon. Now we are shooting for 100% of the population being vaccinated and you need to justify not getting it.
The further we go down this road, the more those options narrow rather than expand. I am some nutter who "lives in a bubble" for preferring to limit my exposure to germs as effective prevention rather than live on prophylactic antibiotics all the time, never mind that one of the outcomes of putting people with CF on antibiotics constantly is a high incidence of C-dif infections which are then treated by surgically removing your colon. Limiting my exposure to other people and their germs is not viewed as a reasonable choice for avoiding that outcome.
I am not seeing similar amounts of muscle put into policy changes that are more family friendly, people friendly etc. Saying there is nothing wrong with developing this stuff ignores the context in which this is occurring. If all of the above were equally accepted answers, I would not get so much ugly and threatening push back for talking about the choices I have made. I should not need to defend the idea that I would just rather not be sick, thanks, and I am willing to limit my social life to have that. But I get outright attacked for that.
So you would be wise to be a tad more skeptical about where such things lead. They tend to lead to promoting one path over another, at the expense of the other, rather than a broadening of options.
There was just a huge wave of Alzheimer's treatments that people were so hopeful might make any dent in the disease. They all failed, apparently because the breakthrough we thought we had made in understanding the disease turned out to be specious. Had the drugs made ANY improvement they'd be on the market and we'd all be bitching about how pharma "likes to make bandaids rather than cures," and that would have been a disservice to the years of toil people put into these drugs.
Not every pharma actor is a good actor. But overall the space is mostly filled with scientists and doctors trying to make people healthier, and mostly failing.
Failing flat, i.e., not making people healthier but not making them sicker either, is not a problem. Failing down, i.e. trying to make people healthier but making them sicker instead, is and has been a huge problem with modern medicine, even when done with the best of intentions.
Yes, the past century has seen great progress in neutralizing infectious disease (though it is likely that the HIV epidemic itself was an "own goal" of basically iatrogenic origin [1]), but nearly everything else, including cancer, is a wash.
Unfortunately, a sober analysis of the benefits and harms of actors in the medical space cannot afford to give much credit for effort or good intentions.
He also survived colon cancer in his late 60s for the same reason and I flew out and took care of my sister after her first mastectomy with her first round of cancer. The doctors attributed my father's survival after they wrote him off for dead to my mother's care. They interviewed her on tape and changed the practices at their clinic based on what she had to say. From what I gather, two different cancer clinics began offering patients German Penaten cream to help their surgical scars heal because that was why my father's 16 inch surgical scar did so well.
I have zero reason to believe you are correct. There are some differences between different diseases. But my life's experience suggests that a) getting fed right b) getting proper care from someone who actually cares about you and c) adequate control over your environment are pretty universal beneficial, regardless of your exact diagnosis.
(But I'm just a woman, so not likely to be listened to. Yes, I'm feeling pretty bitter about that at the moment.)
Are families with two working parents actually less healthy? Do you have a source for that?
We are seeing a huge rise in problem pregnancies, birth defects, etc. There are likely a number of contributing factors to that reality. It isn't PC to wonder if maybe the rise of female careers is at related. That is viewed as antifeminist and so on.
Women routinely take time off work to care for relatives, whether their own children or other relatives. They get no credit for this vital work and how it impacts the health of people.
My experience suggests there isn't any point in trying to prove it. It won't get taken seriously anyway.
It is common knowledge that small kids in daycare have more health issues. My sister, who has a career and works for the CDC, used to quote studies at me about that. She managed to stay home with her only child for the first few years.
But, of course, in searching for info to support the idea that small kids in daycare get sick more, one of the most prominent pieces I can find is a PC piece assuring parents that the increased negative health effects of early daycare "has a protective effect later." Meanwhile, the study completely excludes data on, for example, hospital stays. Looks nicely spun to me.
Other pieces outright admit that staying home is simply not an option for many women and go on to talk about how best to protect your child from germs at daycare rather than exploring statistics. Yet the fact that you can google the question and there are pieces trying to address it at all suggests it is a real issue and parents ask about the problem a lot. But society can't fix it, so it isn't really comfortable to admit that it is a real issue.
Home cooked meals are also generally healthier than takeout, microwave meals, etc. Two career couples tend to not do a lot of cooking from scratch. Diet significantly impacts health.
Aging biology is all about understanding how diseases develop to begin with, and lifestyle interventions are definitely part of that umbrella of research. Those of us who obsess over aging biology tend to prefer thinking about preventative strategies first, and rejuvenation as a fallback.
Fair enough, but there are also plenty of conditions for which these things don’t work adequately, and we absolutely do need to encourage research. I think this is a great move from YC.
They have all kinds of great food to choose from
a) There's no obligation to work on earthquake-ridden cities over any other issue.
b) Mythical Man Month problem; firefighters might be good at extinguishing flame but not repairing earthquake issues, and there's only so many civil engineers to go around.
c) Your comment is proof that no good deed goes unpunished.